Table 1.
TCGA studies and sample numbers used for DNA methylation analyses in this study
| Study | Study name/tumor entity | Tumors | Normals |
|---|---|---|---|
| ACC | Adrenocortical carcinoma | 79 | 0 |
| BLCA | Bladder urothelial carcinoma | 368 | 17 |
| BRCA | Breast invasive carcinoma | 772 | 96 |
| CESC | Cervical squamous cell carcinoma and endocervical adenocarcinoma | 299 | 3 |
| CHOL | Cholangiocarcinoma | 35 | 9 |
| COAD | Colon adenocarcinoma | 265 | 30 |
| DLBC | Lymphoid Neoplasm Diffuse Large B-Cell Lymphoma | 47 | 0 |
| ESCA | Esophageal carcinoma | 182 | 13 |
| GBM | Glioblastoma multiforme | 129 | 2 |
| HNSC | Head and neck squamous cell carcinoma | 481 | 50 |
| KICH | Kidney chromophobe | 60 | 0 |
| KIRC | Kidney renal clear cell carcinoma | 271 | 141 |
| KIRP | Kidney renal papillary cell carcinoma | 243 | 34 |
| LGG | Brain lower grade glioma | 498 | 0 |
| LIHC | Liver hepatocellular carcinoma | 360 | 45 |
| LUAD | Lung adenocarcinoma | 399 | 22 |
| LUSC | Lung squamous cell carcinoma | 337 | 36 |
| MESO | Mesothelioma | 82 | 0 |
| OV | Ovarian adenocarcinomas | 10 | 0 |
| PAAD | Pancreatic adenocarcinoma | 155 | 7 |
| PCPG | Pheochromocytoma and paraganglioma | 152 | 3 |
| PRAD | Prostate adenocarcinoma | 476 | 40 |
| READ | Rectum adenocarcinoma | 91 | 7 |
| SARC | Sarcoma | 244 | 0 |
| SKCM | Skin cutaneous melanoma | 102 | 1 |
| STAD | Stomach adenocarcinoma | 388 | 2 |
| TGCT | Testicular germ cell tumors | 149 | 0 |
| THCA | Thyroid carcinoma | 484 | 54 |
| THYM | Thymoma | 122 | 2 |
| UCEC | Uterine Corpus Endometrial Carcinoma | 404 | 45 |
| UCS | Uterine carcinosarcoma | 56 | 0 |
| UVM | Uveal melanoma | 80 | 0 |